Cees B. de Vos

Bio: Cees B. de Vos is an academic researcher from Maastricht University Medical Centre. The author has contributed to research in topics: Atrial fibrillation & Sinus rhythm. The author has an hindex of 12, co-authored 21 publications receiving 4189 citations. Previous affiliations of Cees B. de Vos include Maastricht University.

Atrial activation time determined by transthoracic Doppler tissue imaging can be used as an estimate of the total duration of atrial electrical activation.

Abstract: Background Currently, the total atrial activation time, as indicated by the P-wave duration using signal-averaged (SA) electrocardiogram (ECG) (SA-ECG), is the most powerful predictor of atrial fibrillation. However, because of practical limitations, this technique is not used in clinical routine. In this study we evaluated several alternative techniques to measure the total atrial activation time, including a new parameter that uses atrial Doppler tissue imaging (DTI). Methods For 30 patients who were in sinus rhythm and underwent a transthoracic echocardiogram, we determined the P-wave duration on surface ECG and SA-ECG, and the interval from the onset of the P wave (lead II) until the onset of the echocardiographic flow Doppler A wave over the mitral valve. In addition, using pulsed wave DTI in the 4-chamber view, we measured the interval of time from initiation of the ECG P wave (lead II) until the peak of the local lateral left atrial (LA) DTI signal. Correlation between the SA-ECG, surface ECG, and echocardiographic parameters were evaluated by Spearman correlation tests. Results All parameters that were used to estimate total atrial activation time showed a significant correlation with the SA-ECG P-wave duration. Although the interval of time from initiation of the ECG P wave until the peak of the local lateral LA DTI signal was significantly longer than the SA-ECG P-wave duration (151.12 ± 19.4 vs 128.4 ± 15.8 milliseconds, respectively, P R = 0.91, P P Conclusion LA DTI is an easy, fast, and reliable method to estimate the total atrial electrical activation time, and may be useful in the identification of those prone to develop atrial fibrillation.

Autonomic trigger patterns and anti-arrhythmic treatment of paroxysmal atrial fibrillation: data from the Euro Heart Survey

Abstract: To investigate the clinical characteristics, management, and outcome of patients with paroxysmal atrial fibrillation (AF) associated with autonomic triggers. Methods and results One thousand five hundred and seventeen patients with paroxysmal AF participated in the Euro Heart Survey on AF. We categorized patients according to trigger pattern as reported by the physician: adrenergic (AF associated with exercise, emotion or during daytime only and absence of vagal triggers), vagal (postprandial or night time only, without presence of adrenergic triggers) and mixed (combination of vagal and adrenergic triggers). Vagal AF was found in 91 patients (6%), adrenergic in 229 patients (15%) and mixed in 175 (12%) patients. Underlying heart disease was equally prevalent in the three groups. Among patients with vagal AF, 73% were treated with non- recommended drugs according to the guidelines. In vagal AF, non-recommended treatment was associated with a shift to persistent or permanent AF in 19% of the patients, compared with none in the group receiving recommended treatment (P ¼ 0.06). Conclusion This study is the first to address the issue of autonomic trigger patterns and AF in a large population. Autonomic trigger patterns were seen frequently in paroxysmal AF patients. Autonomic influences should be taken into con-

2016 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure

Abstract: ACC/AHA : American College of Cardiology/American Heart Association ACCF/AHA : American College of Cardiology Foundation/American Heart Association ACE : angiotensin-converting enzyme ACEI : angiotensin-converting enzyme inhibitor ACS : acute coronary syndrome AF : atrial fibrillation

2014 AHA/ACC/HRS Guideline for the Management of Patients With Atrial Fibrillation: A Report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines and the Heart Rhythm Society

Abstract: Jeffrey L. Anderson, MD, FACC, FAHA, Chair Jonathan L. Halperin, MD, FACC, FAHA, Chair-Elect Nancy M. Albert, PhD, RN, FAHA Biykem Bozkurt, MD, PhD, FACC, FAHA Ralph G. Brindis, MD, MPH, MACC Mark A. Creager, MD, FACC, FAHA[#][1] Lesley H. Curtis, PhD, FAHA David DeMets, PhD[#][1] Robert A

ESC Guidelines for the Diagnosis And Treatment of Acute And Chronic Heart Failure 2008

Abstract: Authors/Task Force Members: John J.V. McMurray (Chairperson) (UK)*, Stamatis Adamopoulos (Greece), Stefan D. Anker (Germany), Angelo Auricchio (Switzerland), Michael Böhm (Germany), Kenneth Dickstein (Norway), Volkmar Falk (Switzerland), Gerasimos Filippatos (Greece), Cândida Fonseca (Portugal), Miguel Angel Gomez-Sanchez (Spain), Tiny Jaarsma (Sweden), Lars Køber (Denmark), Gregory Y.H. Lip (UK), Aldo Pietro Maggioni (Italy), Alexander Parkhomenko (Ukraine), Burkert M. Pieske (Austria), Bogdan A. Popescu (Romania), Per K. Rønnevik (Norway), Frans H. Rutten (The Netherlands), Juerg Schwitter (Switzerland), Petar Seferovic (Serbia), Janina Stepinska (Poland), Pedro T. Trindade (Switzerland), Adriaan A. Voors (The Netherlands), Faiez Zannad (France), Andreas Zeiher (Germany).

ESC guidelines for the diagnosis and treatment of acute and chronic heart failure 2012: The Task Force for the Diagnosis and Treatment of Acute and Chronic Heart Failure 2012 of the European Society of Cardiology. Developed in collaboration with the Heart Failure Association (HFA) of the ESC.

Abstract: ESC guidelines for the diagnosis and treatment of acute and chronic heart failure 2012 : The Task Force for the Diagnosis and Treatment of Acute and Chronic Heart Failure 2012 of the European Society of Cardiology. Developed in collaboration with the Heart Failure Association (HFA) of the ESC